Cargando…
Targeted Therapies and Immune Checkpoint Inhibitors in Primary CNS Lymphoma
SIMPLE SUMMARY: Primary central nervous system lymphoma is a rare disease with limited therapeutic options. A more profound understanding of the molecular mechanisms that underlie this disease has fostered the development of novel therapeutic approaches. Key developments for the treatment of primary...
Autores principales: | Wirsching, Hans-Georg, Weller, Michael, Balabanov, Stefan, Roth, Patrick |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8234854/ https://www.ncbi.nlm.nih.gov/pubmed/34203062 http://dx.doi.org/10.3390/cancers13123073 |
Ejemplares similares
-
CNS side effects of immune checkpoint inhibitors: preclinical models, genetics and multimodality therapy
por: McGinnis, Gwendolyn J, et al.
Publicado: (2017) -
Primary CNS Lymphoma
por: Phillips, Elizabeth H., et al.
Publicado: (2014) -
Primary CNS lymphoma commonly expresses immune response biomarkers
por: Ou, Alexander, et al.
Publicado: (2020) -
T-cell lymphoma secondary to checkpoint inhibitor therapy
por: Anand, Kartik, et al.
Publicado: (2020) -
Sex-Specific Differences in Primary CNS Lymphoma
por: Roetzer, Thomas, et al.
Publicado: (2020)